rss
Br J Ophthalmol 2005;89:266-268 doi:10.1136/bjo.2004.049841
  • Clinical science
    • Scientific reports

A randomised, placebo controlled clinical trial of the aldose reductase inhibitor CT-112 as management of corneal epithelial disorders in diabetic patients

  1. M Nakahara1,
  2. K Miyata1,
  3. S Otani1,
  4. T Miyai1,
  5. R Nejima1,
  6. S Yamagami2,
  7. S Amano2
  1. 1Meiwakai Medical Foundation, Miyata Eye Hospital, Miyakonojo, Miyazaki, Japan
  2. 2Department of Ophthalmology, University of Tokyo School of Medicine, Tokyo, Japan
  1. Correspondence to: Shiro Amano 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655 Japan; amanos-tkyumin.ac.jp
  • Accepted 1 August 2004

Abstract

Aim: To evaluate the efficacy of topical aldose reductase inhibitor CT-112 (5-[3-ethoxy-4-pentyloxyphenyl]-2,4-thiazolidinedione) on corneal epithelial barrier function in diabetic patients.

Methods: This was a prospective, randomised, double masked placebo controlled study. 34 eyes of 34 diabetic patients were randomly assigned treatment with 0.25% eye drops of CT-112 (n = 22) or a placebo (n = 12) four times a day for 8 weeks. Corneal fluorescein staining and corneal sensation were examined before treatment as well as 4 and 8 weeks after administration. Corneal epithelial permeability to fluorescence was measured with an anterior fluorophotometer.

Results: Average scores of superficial punctate keratopathy and corneal sensitivity did not differ significantly between the two groups at any time. Whereas average fluorescein concentrations did not differ significantly for the CT-112 and placebo groups before treatment, they did differ significantly 4 and 8 weeks after treatment (4 weeks, p = 0.0327; 8 weeks, p = 0.0143).

Conclusion: The topical aldose reductase inhibitor, CT-112 improves the corneal epithelial barrier function in diabetic patients.

Footnotes

  • The authors have no commercial or proprietary interest in the products or companies mentioned in the current article.

This Article

  1. Abstract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Social bookmarking

Register for free content


Free sample
 This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
View free sample issue >>

Free archive
The full back archive is now available for BJO. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.